Grifols, S.A.
GIKLY
Other OTC5.13
USD
+0.03
- -
CIK
0001438569
ISIN
US3984382008
CUSIP
398438200
Return %
Stock
S&P500
1Y
-27.13
18.21
3Y
-31.60
64.38
5Y
-60.54
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jose Ignacio Abia Buenache
- Full Time Employees
- 25,258
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Avinguda de la Generalitat, 152 Barcelona CT Spain 08174
- IPO Date
- Jan 20, 2010
- CIK
- 0001438569
- Website
- grifols.com
- Similar Companies
- Business
- Grifols, S.A. (GIKLY) is a global healthcare company and leading producer of plasma-derived medicines that develops, manufactures and markets protein therapies for patients with rare and chronic diseases, including immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors; diagnostic solutions for transfusion medicine such as blood typing reagents, instruments and software; biological supplies for life-science research and clinical trials; and hospital products encompassing intravenous solutions, clinical nutrition and medical devices. The company operates through three primary divisions—Bioscience, Diagnostics and Hospital—serving therapeutic areas including immunology, infectious diseases, pulmonology, neurology, hepatology, hematology and intensive care, with products distributed to hospitals, pharmacies, blood banks and healthcare professionals in over 110 countries. Founded in 1909 and headquartered in Sant Cugat del Vallès, Barcelona, Spain, Grifols maintains the world's largest private network of approximately 400 plasma collection centers across North America, Europe, Africa, the Middle East and China via its partnership with Shanghai RAAS. In recent developments, Grifols announces plans in mid-2025 to construct a new manufacturing facility in Spain to double its plasma fractionation capacity in Europe as part of its Value Creation Plan, supporting 7% revenue growth to EUR 3,677 million and net profit of EUR 177 million in the first half of 2025; completes the delisting of Biotest in June 2025 following its 2022 acquisition to expand plasma therapies and European operations; concludes in December 2024 a balance sheet improvement process through a EUR 1.3 billion private placement of senior secured notes and revolving credit facility extension, backed by global investors; finalizes in June 2024 the sale of a 20% equity stake in Shanghai RAAS to Haier Group for approximately USD 1.8 billion, establishing a strategic alliance; secures investor approval in November 2025 for amendments to its EUR 1.3 billion secured notes and receives positive credit rating actions from Fitch and Moody's; and undergoes governance changes including the appointment of Anne-Catherine Berner as Chair in June 2025, Rahul Srinivasan as CFO in July 2024 and Nacho Abia as CEO in April 2024.
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript